Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Valve-in-valve TAVR vs. redo SAVR | New imaging vendor raises $36M | Monopoly accusations lead to lawsuit
Wednesday, December 13, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Early survival data favor valve-in-valve TAVR over redo SAVR—long-term data flip the script

Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.

READ MORE >
According to the U.S. government, Asante Health System and one of its surgeons knowingly submitted false claims to Medicare, Medicaid and TRICARE for more than six years. Heart surgery surgeons.
Share on Twitter Share on Facebook Share on Linkedin

Early survival data favor valve-in-valve TAVR over redo SAVR—long-term data flip the script

Share on Twitter Share on Facebook Share on Linkedin
According to the U.S. government, Asante Health System and one of its surgeons knowingly submitted false claims to Medicare, Medicaid and TRICARE for more than six years. Heart surgery surgeons.
Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.
READ MORE >

New imaging vendor focused on AI, robotics raises $36M with help from GE Healthcare

The funds are expected to go toward bringing in new employees and accelerating the development of a new cardiac imaging offering. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

New imaging vendor focused on AI, robotics raises $36M with help from GE Healthcare

Share on Twitter Share on Facebook Share on Linkedin
The funds are expected to go toward bringing in new employees and accelerating the development of a new cardiac imaging offering. 
READ MORE >

Nevada health system accused of creating a heart surgery monopoly in new lawsuit

The health system allegedly ended an ongoing contract with little notice, leaving clinicians and patients without the services of a cardiovascular surgery program. 

READ MORE >
A gavel and a stethoscope
Share on Twitter Share on Facebook Share on Linkedin

Nevada health system accused of creating a heart surgery monopoly in new lawsuit

Share on Twitter Share on Facebook Share on Linkedin
A gavel and a stethoscope
The health system allegedly ended an ongoing contract with little notice, leaving clinicians and patients without the services of a cardiovascular surgery program. 
READ MORE >

Featured Articles

Deaths from CVD are on the rise, cardiologists warn—high blood pressure, obesity remain 2 primary culprits

Cardiovascular disease remains one of the leading causes of mortality in the world, responsible for nearly 20 million deaths in 2022 alone. 

READ MORE >
Newsweek ranked the 50 best heart hospitals in the world
Share on Twitter Share on Facebook Share on Linkedin

Deaths from CVD are on the rise, cardiologists warn—high blood pressure, obesity remain 2 primary culprits

Share on Twitter Share on Facebook Share on Linkedin
Newsweek ranked the 50 best heart hospitals in the world
Cardiovascular disease remains one of the leading causes of mortality in the world, responsible for nearly 20 million deaths in 2022 alone. 
READ MORE >

Shockwave C²⁺ Now Available in the U.S.

Sponsored by Shockwave Medical

Shockwave C2+ upgrades your calcium-cracking capabilities with 50% more pulses intended to treat longer lesions with diffuse calcium, eccentric and nodular calcium. US: Rx only. See Important Safety Information: http://bit.ly/3iEq7fC SPL-70478 Rev. A. 

READ MORE >
Shockwave Newsletter
Share on Twitter Share on Facebook Share on Linkedin

Shockwave C²⁺ Now Available in the U.S.

Sponsored by Shockwave Medical

Share on Twitter Share on Facebook Share on Linkedin
Shockwave Newsletter
Shockwave C2+ upgrades your calcium-cracking capabilities with 50% more pulses intended to treat longer lesions with diffuse calcium, eccentric and nodular calcium. US: Rx only. See Important Safety Information: http://bit.ly/3iEq7fC SPL-70478 Rev. A. 
READ MORE >

Beloved cardiologist remembered as a ‘master clinician’ and 'friend to all'

Adolph M. Hutter, MD, spent more than 50 years with Massachusetts General Hospital and worked with multiple professional sports teams. In addition, he served as president of the American College of Cardiology in 1992-1993. 

READ MORE >
Adolph M. Hutter, MD, cardiologist and past president of the American College of Cardiology
Share on Twitter Share on Facebook Share on Linkedin

Beloved cardiologist remembered as a ‘master clinician’ and 'friend to all'

Share on Twitter Share on Facebook Share on Linkedin
Adolph M. Hutter, MD, cardiologist and past president of the American College of Cardiology
Adolph M. Hutter, MD, spent more than 50 years with Massachusetts General Hospital and worked with multiple professional sports teams. In addition, he served as president of the American College of Cardiology in 1992-1993. 
READ MORE >

In Case You Missed It

Cardiawave’s non-invasive ultrasound therapy impresses cardiologists early on—could it be an alternative to SAVR, TAVR?

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

READ MORE >
Cardiawave Valvosoft non-invasive ultrasound therapy
Share on Twitter Share on Facebook Share on Linkedin

Cardiawave’s non-invasive ultrasound therapy impresses cardiologists early on—could it be an alternative to SAVR, TAVR?

Share on Twitter Share on Facebook Share on Linkedin
Cardiawave Valvosoft non-invasive ultrasound therapy
While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.
READ MORE >

New formula could mean diabetes and weight loss drugs such as semaglutide are only needed every 4 months

GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year. 

READ MORE >
Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.
Share on Twitter Share on Facebook Share on Linkedin

New formula could mean diabetes and weight loss drugs such as semaglutide are only needed every 4 months

Share on Twitter Share on Facebook Share on Linkedin
Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.
GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year. 
READ MORE >

In Other News

House passes ‘landmark’ bill to juice healthcare price transparency

Bipartisan legislation intended to lower healthcare costs by lifting price transparency has made it through the U.S. House of Representatives.

READ MORE >
Lower Costs More Transparency Act
Share on Twitter Share on Facebook Share on Linkedin

House passes ‘landmark’ bill to juice healthcare price transparency

Share on Twitter Share on Facebook Share on Linkedin
Lower Costs More Transparency Act
Bipartisan legislation intended to lower healthcare costs by lifting price transparency has made it through the U.S. House of Representatives.
READ MORE >

60-year-old radiology practice sells its outpatient imaging center business to private equity-backed platform company

Southtowns Radiology said the deal will allow for expansion on the outpatient side while also letting it retain autonomy to operate its private practice. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

60-year-old radiology practice sells its outpatient imaging center business to private equity-backed platform company

Share on Twitter Share on Facebook Share on Linkedin
Southtowns Radiology said the deal will allow for expansion on the outpatient side while also letting it retain autonomy to operate its private practice. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Strokes after PFA | FDA links weight loss pill to cardiovascular risks | Stereotaxis to acquire Robocath | Antidepressants & SCD
Heartflow sues Cleerly | Outgoing SCAI president reflects on a busy year | FDA clears next-generation heart device
Heartflow sues AI rival Cleerly | Turning data into actionable insights | FDA clears new algorithms | Key innovations at ACC.26
FDA's warning for cath labs | Stryker to acquire IVL company | New data on resistant hypertension | More patients, fewer doctors
Fraud allegations lead to $4.75M settlement | Hospital sues cardiology practice | A new business model | Whoop raises $575M
FDA clears AI for cardiac amyloidosis | SVS works to improve vascular care | Paravalvular leak after TTVR
Week in Review: Cardiologist says he was fired for speaking out | Millions of devices recalled | Hospital sues practice

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …12
    • Page 13
    • Page 14
    • Page 15
    • Current page 16
    • Page 17
    • Page 18
    • Page 19
    • Page 20 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup